Multiorgan Dysfunction and Associated Prognosis in Transthyretin Cardiac Amyloidosis.
Adam IoannouChristian NitscheAldostefano PorcariRishi K PatelYousuf RazviMuhammad Umaid RaufAna Martinez-NaharroLucia VenneriAntonella AcciettoLucrezia NettiFrancesco BanderaRuta VirsinskaiteTushar KotechaDan KnightAviva PetrieCarol WhelanAshutosh WechalekarHelen LachmannPhilip N HawkinsJulian David GillmoreMarianna FontanaPublished in: Journal of the American Heart Association (2024)
Cardiac and noncardiac biomarker abnormalities were common and reflect the complex and multifaceted nature of ATTR-CA, with a wide range of biomarkers remaining independently associated with mortality. Clinical trials are needed to investigate whether biomarker abnormalities represent modifiable risk factors that if specifically targeted could improve outcomes.